DataMEDS AI, Inc. filed a Form 8-K on November 16, 2026, disclosing its entry into an at-the-market sales agreement with Dawson James Securities, Inc. to offer and sell shares of its common stock from time to time on The Nasdaq Capital Market.
Key Highlights
- ATM Agreement Signed: DataMEDS AI entered into a sales agreement with Dawson James Securities, Inc. on November 16, 2026, to conduct an at-the-market offering of its common stock.
- Commission Rate: The company agreed to pay the sales agent a fixed commission rate of 3.0% of the aggregate gross proceeds from shares sold under the agreement.
- No Obligation to Sell: According to the filing, the company is not obligated to make any sales of shares under the sales agreement.
- Termination Provision: Either party may terminate the sales agreement in its sole discretion at any time by giving ten days' prior notice to the other party.
- Registration Statement: The shares are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-295078), declared effective by the SEC on May 7, 2026, and a prospectus supplement dated November 16, 2026.
- Emerging Growth Company: The filing identifies DataMEDS AI as an emerging growth company as defined under applicable securities regulations.
DataMEDS AI Establishes At-the-Market Equity Facility with Dawson James
DataMEDS AI, Inc. (NASDAQ:MEDS) disclosed in its November 16, 2026, Form 8-K that it entered into an ATM sales agreement with Dawson James Securities, Inc. Under the terms of the sales agreement, the sales agent may sell shares of the company's common stock, par value $0.0001 per share, in transactions deemed to be an "at-the-market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Sales may be made directly on or through The Nasdaq Capital Market, any other existing trading market for the common stock, in negotiated transactions at market prices prevailing at the time of sale, or by any other method permitted by law, according to the filing.
The filing states that the company may instruct the sales agent not to sell shares if sales cannot be effected at or above a price designated by the company from time to time. The company will pay Dawson James Securities a fixed commission of 3.0% of the aggregate gross proceeds of the sales price of shares sold, and has agreed to provide customary indemnification and contribution rights. The company also agreed to reimburse the sales agent for certain expenses, the filing disclosed.
The shares are being offered and sold pursuant to the company's shelf registration statement on Form S-3 (File No. 333-295078), filed with the SEC on April 15, 2026, and declared effective on May 7, 2026, together with a prospectus supplement dated November 16, 2026. The company's counsel, Sheppard, Mullin, Richter and Hampton LLP, provided a legal opinion regarding the legality of the shares, which was filed as Exhibit 5.1. The full text of the sales agreement was filed as Exhibit 10.1 and is incorporated by reference into the filing.
What Was Disclosed
DataMEDS AI, Inc. reported the execution of an at-the-market sales agreement with Dawson James Securities, Inc. on November 16, 2026, establishing a facility to sell common stock from time to time, subject to a 3.0% commission, with no obligation on the company to make any sales.




Please wait processing your request...